Chronic lymphocytic leukaemia

Research output: Contribution to journalArticle

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
DOIs
Publication statusAccepted/In press - Feb 10 2015

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Lymphocytosis
Western World
Lymphoproliferative Disorders
Leukemia
Therapeutics
Spleen
Lymph Nodes
Bone Marrow
Recurrence
Survival

Keywords

  • Chronic lymphocytic leukaemia
  • Leukaemias
  • Lymphoproliferative disorders

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Chronic lymphocytic leukaemia. / Scarfò, Lydia; Ferreri, Andrés J M; Ghia, Paolo.

In: Critical Reviews in Oncology/Hematology, 10.02.2015.

Research output: Contribution to journalArticle

@article{d137a61b0ee649f7be6d5cfbfa002eff,
title = "Chronic lymphocytic leukaemia",
abstract = "Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.",
keywords = "Chronic lymphocytic leukaemia, Leukaemias, Lymphoproliferative disorders",
author = "Lydia Scarf{\`o} and Ferreri, {Andr{\'e}s J M} and Paolo Ghia",
year = "2015",
month = "2",
day = "10",
doi = "10.1016/j.critrevonc.2016.06.003",
language = "English",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Chronic lymphocytic leukaemia

AU - Scarfò, Lydia

AU - Ferreri, Andrés J M

AU - Ghia, Paolo

PY - 2015/2/10

Y1 - 2015/2/10

N2 - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.

AB - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.

KW - Chronic lymphocytic leukaemia

KW - Leukaemias

KW - Lymphoproliferative disorders

UR - http://www.scopus.com/inward/record.url?scp=84979659027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979659027&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.06.003

DO - 10.1016/j.critrevonc.2016.06.003

M3 - Article

AN - SCOPUS:84979659027

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -